Drugs / Simvastatin
Simvastatin
also known as
Zocor · MK0733 · SIM · SMV · Simvastatin (ZOCOR) · Simvastatine · Brand name: Simvastatin Normon, 40 mg · C10AA01 · +16 more
Small molecule targets ABCB1, HMGCR, PTEN via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 13 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Cholib | — | 2013-08-26 | europa.eu ↗ |
| Label expansions (11) | US (FDA) | ZOCOR | — | 1995-06-30 – 2003-04-16 | fda.gov ↗ |
| Approved | US (FDA) | ZOCOR | — | 1991-12-23 | fda.gov ↗ |
Trials 383 · started per year
today
US approved 1991
EU approved 2013
1
1
1
1
2
7
3
11
6
15
25
29
28
19
18
29
19
21
12
13
15
9
12
9
11
10
7
10
5
12
10
7
1
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 014 trials | ||||||
| Phase 0 | NCT07031778 | Jan 2025 overdue | bone disorder | University of Granada | Recruiting | No outcome recorded |
| Phase 0 | NCT05771675 | Oct 2024 → Dec 2026 expected | chronic pancreatitis, recurrent acute pancreatitis | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT06273111 | Apr 2024 → Jul 2025 | skin hemangioma | Joyce Teng | Unknown | No outcome recorded |
| Phase 0 | NCT05878158 | Apr 2023 → Jan 2024 | exposure, dental pulp | Ahmad Elheeny | Unknown | No outcome recorded |
| Phase 0 | NCT05464810 | Sep 2022 → Apr 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 0 | NCT04457089 | Jan 2021 → Nov 2024 | ovarian cancer | Marc Goodman | Completed | No outcome recorded |
| Phase 0 | NCT04514029 | Aug 2020 → Nov 2023 overdue | lymphoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02971410 | Apr 2017 → Nov 2021 | plasma cell myeloma | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT03011931 | Mar 2016 → Jan 2019 | celiac disease | Entero Therapeutics | Completed | No outcome recorded |
| Phase 0 | NCT02534376 | Sep 2015 → Feb 2019 | prostate cancer | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT02548936 | Apr 2015 → Oct 2016 | atherosclerosis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02285738 | Dec 2014 → Jul 2017 | cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT01764451 | Mar 2012 → Jan 2016 | famililal cerebral cavernous malformations | University of New Mexico | Terminated | No outcome recorded |
| Phase 0 | NCT00769210 | May 2005 → Jul 2008 | heart failure | University of Utah | Completed | No outcome recorded |
| Phase 175 trials | ||||||
| Phase 1 | NCT07389304 | Mar → Dec 2026 expected | — | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07378293 | Mar → Dec 2026 expected | diabetes mellitus | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06925490 | Jun 2025 → Sep 2026 expected | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06948747 | May → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06478940 | Aug 2024 → Aug 2025 | dental pulp disorder | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT06186622 | Jan → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05542095 | May 2023 | COVID-19, olfactory nerve disorder | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT05580250 | Nov → Dec 2022 | — | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT06207682 | Jun → Aug 2022 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT05306379 | Jan → Apr 2022 | — | Aurinia Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04859452 | May → Jul 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04824898 | Jan 2021 → Sep 2022 | periodontitis, aggressive | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT05008068 | Aug 2019 → Sep 2020 | — | British University In Egypt | Completed | No outcome recorded |
| Phase 1 | NCT03929744 | Jun 2019 → Nov 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03889795 | Jun 2019 → Dec 2026 expected | malignant pancreatic neoplasm | Danae Hamouda, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03728101 | Nov → Dec 2018 | — | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03801733 | Jun → Nov 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03086291 | Jan 2018 → Sep 2020 | gastric cancer | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT03329118 | Nov → Dec 2017 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03174041 | Apr → Jun 2017 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02817243 | Mar → Jul 2016 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02675309 | Feb → Mar 2016 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02685462 | Jan → Feb 2016 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02547402 | Dec 2015 → Jan 2016 | acute kidney injury | Complexa, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02542969 | Sep → Oct 2015 | — | Madrigal Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02406261 | Apr → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02431013 | Apr → Aug 2015 | hyperlipidemia, peripheral arterial disease | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT02447601 | Mar → May 2015 | type 2 diabetes mellitus | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02390843 | Feb 2015 → Sep 2019 | Ewing sarcoma, Wilms tumor, clear cell sarcoma, germ cell tumor +7 | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02197234 | Dec 2014 → Apr 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02300259 | Nov 2014 → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02360826 | Jun 2014 → Jul 2016 | — | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 1 | NCT02156492 | Jun → Dec 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02017639 | Jan 2014 → Mar 2016 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01978327 | Nov 2013 → Mar 2014 | Alzheimer disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01979185 | Nov → Dec 2013 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01953835 | Oct 2013 → Mar 2014 | systemic lupus erythematosus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01960140 | Oct → Dec 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01725230 | Nov 2012 → Jan 2013 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01642862 | Jul 2012 → Jul 2013 | celiac disease | University of Zurich | Terminated | No outcome recorded |
| Phase 1 | NCT01689623 | Jun → Aug 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01870466 | Jun 2012 → Sep 2013 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01632566 | Jun 2012 → Apr 2013 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01486433 | Nov 2011 → Mar 2012 | hypertriglyceridemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01469468 | Nov → Dec 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01445860 | Aug → Sep 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01520077 | Jul 2011 → Jan 2015 | alopecia areata | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT01383395 | Jun → Sep 2011 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01304329 | Feb → Apr 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01138072 | Jun → Aug 2010 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01147692 | May → Aug 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01101568 | Apr → Jun 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01096940 | Mar → Aug 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01103739 | Mar → May 2010 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01299597 | Jan → Feb 2010 | sleep disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00994773 | Dec 2009 → Oct 2011 | hepatitis B virus infection | Bader, Ted, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT00935259 | Jul → Oct 2009 | hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00987558 | Jun → Aug 2009 | epilepsy | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00924430 | Jun → Jul 2009 | type 2 diabetes mellitus | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00828282 | Mar 2009 → Jan 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma | John Haslip | Completed | No outcome recorded |
| Phase 1 | NCT00538044 | Jan 2009 → Jan 2012 | pulmonary hypertension | Capital Medical University | Unknown | No outcome recorded |
| Phase 1 | NCT01821027 | Aug → Sep 2008 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00736606 | Aug → Sep 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00504439 | Jun → Sep 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00652431 | May → Jul 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 1 | NCT00495729 | Apr → Aug 2007 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00377442 | Aug 2006 → Apr 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00309374 | Mar → Jul 2006 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT02183623 | Sep → Oct 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00255242 | Jul 2004 → Mar 2008 | cystic fibrosis | Akron Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02587390 | May → Jul 2000 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02187536 | Apr → May 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00017758 | — | HIV infectious disease, lipodystrophy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00365001 | ? → Apr 2008 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00000941 | ? → Mar 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/214 trials | ||||||
| Phase 1/2 | NCT07392541 | Jan 2026 → Jan 2028 expected | biliary tract cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06553157 | Sep 2024 → Jul 2025 | cancer, platinum-induced ototoxicity | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT06030622 | Apr → Dec 2024 | malignant pancreatic neoplasm | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT04652089 | Dec 2020 → Sep 2021 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT03599609 | Mar 2018 → Jan 2020 | sickle cell disease, stroke disorder | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 1/2 | NCT02061397 | Mar 2014 → Dec 2019 | lymphangioleiomyomatosis, tuberous sclerosis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/2 | NCT01654562 | Dec 2012 → Jul 2013 | choroideremia | University of Alberta | Terminated | No outcome recorded |
| Phase 1/2 | NCT01702246 | Feb 2012 → May 2015 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 1/2 | NCT01092572 | May 2010 | autoinflammatory syndrome, cystic fibrosis | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00795288 | Aug 2008 → Feb 2013 | subarachnoid hemorrhage | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT00508027 | Jun 2007 → Dec 2011 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 1/2 | NCT00281476 | Feb 2006 → Nov 2007 | plasma cell myeloma | Vejle Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00180713 | Oct 2005 → Oct 2008 | pulmonary hypertension | Imperial College London | Completed | No outcome recorded |
| Phase 1/2 | NCT00235963 | Dec 2002 → Jan 2006 | intracranial vasospasm, subarachnoid hemorrhage | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 269 trials | ||||||
| Phase 2 | NCT07625930 | Jan 2027 → Apr 2029 expected | gastroesophageal adenocarcinoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07662785 | Aug 2026 → Aug 2027 expected | xanthoma | Klira Skin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07213557 | Mar 2026 → Sep 2027 expected | gastroesophageal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT07307989 | Aug 2025 → Jul 2029 expected | hyperlipidemia, ischemic stroke | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07003815 | Jun 2025 → Dec 2026 expected | biliary tract cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06437574 | Jul 2024 → Feb 2028 expected | prostate cancer | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07264842 | Jun 2024 → Apr 2026 overdue | dental pulp necrosis | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05586360 | Mar 2024 → Mar 2027 expected | prostate cancer | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 2 | NCT05821556 | Jun 2023 → Aug 2026 overdue | pancreatic adenocarcinoma | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT05550415 | Aug 2022 → May 2025 overdue | statin toxicity, triple-negative breast carcinoma | Indonesia University | Recruiting | No outcome recorded |
| Phase 2 | NCT04985201 | Nov 2021 → Dec 2022 | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 2 | NCT04698941 | Jul → Dec 2021 | small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 2 | NCT06632834 | Aug 2020 → Jan 2025 overdue | dilated cardiomyopathy | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04301271 | Aug 2020 → Jun 2024 | major depressive disorder, obesity disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT04348695 | Apr 2020 → Jan 2021 | COVID-19 | HM Hospitales | Completed | No outcome recorded |
| Phase 2 | NCT03324425 | Mar 2020 → Dec 2028 expected | breast cancer | Baylor Breast Care Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03329599 | Feb 2019 → Dec 2021 | atherosclerosis | Northern California Institute of Research and Education | Completed | No outcome recorded |
| Phase 2 | NCT03775070 | Jan 2019 → Jul 2022 | dilated cardiomyopathy | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03400826 | Aug 2018 → Jul 2026 overdue | uterine corpus leiomyoma | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT03454529 | Mar 2018 → Oct 2021 | invasive breast carcinoma | Michael Simon | Completed | No outcome recorded |
| Phase 2 | NCT04418089 | Jan 2018 → May 2019 | breast cancer, chemotherapy-induced toxicity | Indonesia University | Completed | No outcome recorded |
| Phase 2 | NCT03150459 | Jul 2017 → Mar 2018 | cirrhosis of liver | Judit Pich | Completed | No outcome recorded |
| Phase 2 | NCT02946424 | Jul 2017 → Sep 2023 | osteoporosis, spinal cord injury | Craig Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02968810 | Jun 2017 → May 2023 overdue | cirrhosis of liver, hepatocellular carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03192293 | Jan 2017 → Jan 2019 | breast cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT02743364 | Sep 2016 → Oct 2019 | acute pancreatitis | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02360618 | Oct 2015 → Jan 2018 | infiltrating bladder urothelial carcinoma | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 2 | NCT03400475 | Apr 2015 → Oct 2016 | mucositis | Ahmed Mohamed Mahrous | Completed | No outcome recorded |
| Phase 2 | NCT02399709 | Apr → Oct 2015 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02161822 | Oct 2014 → Dec 2020 | rectum adenocarcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04183387 | Sep 2014 → Jan 2016 | uveitis | Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology | Completed | No outcome recorded |
| Phase 2 | NCT02096588 | May 2014 → Apr 2017 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT02104193 | Apr 2014 → Nov 2015 | metastatic malignant neoplasm in the brain | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02433535 | Dec 2013 → Aug 2017 | asthma | University of California, Davis | Withdrawn | No outcome recorded |
| Phase 2 | NCT02026583 | Dec 2013 → Apr 2017 | colorectal cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01771198 | Aug 2012 → Jul 2015 | sinusitis | University of Montreal Hospital Centre (CHUM) | Terminated | No outcome recorded |
| Phase 2 | NCT01665950 | Aug 2012 → Oct 2014 | bipolar disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01517893 | Jan 2012 → Dec 2013 | generalized vitiligo | John Harris | Completed | No outcome recorded |
| Phase 2 | NCT01561482 | Jan 2012 → Jul 2014 | prostate carcinoma | Nicholas Mitsiades | Withdrawn | No outcome recorded |
| Phase 2 | NCT01439555 | Nov 2011 → Nov 2017 | Alzheimer disease | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT01441349 | Aug 2011 → Oct 2022 | small cell lung carcinoma | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 2 | NCT01332617 | Apr 2011 → Feb 2018 | plasma cell myeloma | University of Louisville | Withdrawn | No outcome recorded |
| Phase 2 | NCT01281761 | Nov 2010 → Sep 2012 | colorectal cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01156545 | Oct 2010 → Dec 2016 | non-small cell lung carcinoma | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT01225263 | Sep 2010 → Jan 2015 | migraine disorder | Rami Burstein | Completed | No outcome recorded |
| Phase 2 | NCT01190462 | Aug 2010 → Aug 2012 | colorectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01105975 | Apr 2010 → Jun 2011 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01110785 | Apr 2010 → Apr 2012 | colorectal cancer | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01005290 | Oct 2009 → Oct 2010 | hypertensive disorder | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00939822 | Mar 2009 → Sep 2013 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00567307 | Jan → Dec 2009 | cardiovascular disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00718328 | Oct 2008 → Jun 2009 | intracerebral hemorrhage | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00944463 | Oct 2008 → Sep 2013 | malignant pancreatic neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00807950 | Mar 2008 → Dec 2014 | breast cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT00528580 | Feb 2008 → Sep 2011 | infectious disease with sepsis | University of Chicago | Terminated | No outcome recorded |
| Phase 2 | NCT00575965 | Nov 2007 → Dec 2011 | Waldenstrom macroglobulinemia | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00503763 | Sep 2007 → Mar 2009 | smoldering plasma cell myeloma | Meir Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00354640 | Jun 2006 → Oct 2008 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00452244 | May 2006 → Feb 2011 | lung cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00321802 | Apr 2006 → Dec 2012 | paroxysmal atrial fibrillation | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT00452634 | Apr 2006 → Nov 2009 | small cell lung carcinoma | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2 | NCT00334542 | Mar 2006 → Jun 2009 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00359281 | Mar 2006 → Nov 2007 | — | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00313859 | Sep 2005 → Aug 2007 | colorectal cancer, metastatic neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01500577 | Apr 2005 → Nov 2012 | breast cancer | European Institute of Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00399867 | Apr 2005 → Apr 2007 | plasma cell myeloma | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 2 | NCT00486044 | Feb 2005 → Jun 2009 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00594191 | Mar 2004 → Apr 2007 | cirrhosis of liver, portal hypertension | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 2 | NCT00441844 | Oct 2002 → Jul 2005 | type 1 diabetes mellitus | University of California, Davis | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT04971577 | Feb 2022 → Mar 2027 expected | alcohol abuse, fibrotic liver disease | Anna Cruceta | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04301336 | Nov 2019 → Nov 2020 | sickle cell disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT03780673 | Jan 2019 → Dec 2022 | cirrhosis of liver | Judit Pich | Completed | No outcome recorded |
| Phase 2/3 | NCT03490097 | Dec 2017 → May 2018 | chronic hepatitis C virus infection, metabolic syndrome X | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT02252328 | Sep 2015 → Aug 2018 | uveitis | University College, London | Unknown | No outcome recorded |
| Phase 2/3 | NCT01338324 | Apr 2010 → Jun 2011 | celiac disease | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00676897 | Feb 2008 → Dec 2010 | infectious disease with sepsis | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00693576 | Apr 2007 → May 2008 | — | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00109382 | May 2003 → Feb 2007 | transient ischemic attack | University of Calgary | Completed | No outcome recorded |
| Phase 386 trials | ||||||
| Phase 3 | NCT05963568 | Apr 2026 → Jan 2029 expected | stroke disorder | Northern California Institute of Research and Education | Recruiting | No outcome recorded |
| Phase 3 | NCT03654053 | Oct 2020 → Dec 2026 expected | cirrhosis of liver | VA Office of Research and Development | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04133792 | Oct 2020 → Mar 2028 expected | primary sclerosing cholangitis | Annika Bergquist | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04343001 | Oct 2020 → Apr 2021 | COVID-19 | London School of Hygiene and Tropical Medicine | Withdrawn | No outcome recorded |
| Phase 3 | NCT03971019 | Mar 2019 → May 2024 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03435744 | Jan 2019 → Jun 2021 | major depressive disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 3 | NCT03131726 | Jan 2018 → Jan 2027 expected | disease of orbital part of eye adnexa | Lund University | Recruiting | No outcome recorded |
| Phase 3 | NCT04021498 | Sep 2017 → Mar 2025 | recurrent acute pancreatitis | Enrique de-Madaria | Terminated | No outcome recorded |
| Phase 3 | NCT02850081 | Jun 2017 → Mar 2020 | carotid stenosis, stroke disorder | Columbia University | Terminated | No outcome recorded |
| Phase 3 | NCT02713945 | Jan 2017 → Mar 2023 | Noonan syndrome | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 3 | NCT03134157 | Aug 2016 → Jun 2021 | female infertility | Royan Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT03402204 | Apr → Oct 2014 | ischemic stroke | Thammasat University | Completed | No outcome recorded |
| Phase 3 | NCT01999309 | Oct 2013 → Dec 2019 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Iris Sommer | Completed | No outcome recorded |
| Phase 3 | NCT01944176 | Sep 2013 → Aug 2014 | chronic obstructive pulmonary disease | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT01702298 | Dec 2012 → May 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01313702 | Oct 2012 → Apr 2014 | cardiovascular disorder | Hospital do Coracao | Withdrawn | No outcome recorded |
| Phase 3 | NCT01651728 | Jul 2012 → Aug 2013 | pneumonia | Indonesia University | Unknown | No outcome recorded |
| Phase 3 | NCT01646437 | Jun 2012 → Jun 2020 | cardiovascular disorder | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01321255 | Jan 2012 → May 2014 | myocardial infarction | National Center for Cardiovascular Research Carlos III | Completed | No outcome recorded |
| Phase 3 | NCT00994903 | Oct 2011 → Sep 2013 | intestinal neoplasm | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 3 | NCT01335997 | May 2011 → Jan 2012 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01294683 | Feb 2011 → Jan 2012 | hyperlipidemia, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01326676 | Feb 2011 → Jul 2012 | cardiovascular disorder | Imperial College London | Withdrawn | No outcome recorded |
| Phase 3 | NCT01266434 | Jan 2011 → Feb 2016 | asthma | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT01095185 | Nov 2010 → Sep 2013 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension, portal vein thrombosis | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 3 | NCT02134626 | Aug 2010 → Apr 2014 | cirrhosis of liver, esophageal varices, portal hypertension | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| Phase 3 | NCT01057537 | Jun 2010 → Jul 2012 | cardiovascular disorder | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT01238094 | Apr 2010 → Nov 2013 | colorectal cancer | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02070133 | May 2009 → Mar 2013 | chronic obstructive pulmonary disease | Hospital Universitari Son Dureta | Completed | No outcome recorded |
| Phase 3 | NCT00782184 | Nov 2008 → Sep 2010 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00738972 | Jan 2008 → Aug 2010 | hypertensive disorder | Fundación Lindavista del Corazón AC | Terminated | No outcome recorded |
| Phase 3 | NCT00653523 | Dec 2007 → Jun 2009 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00973115 | Nov 2007 → Aug 2009 | hyperlipidemia | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00535405 | Nov 2007 → Mar 2009 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00525824 | Aug 2007 → Sep 2008 | atherosclerosis, coronary artery disorder, hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00496730 | Jul 2007 → Aug 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00479882 | Jun 2007 → Jun 2008 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00491530 | Jun 2007 → Nov 2008 | hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00465088 | Apr 2007 → Feb 2008 | hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00462748 | Mar 2007 → Jun 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00479713 | Feb 2007 → Mar 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00409773 | Jan 2007 → Jul 2008 | hyperlipidemia, metabolic syndrome X | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00362934 | Oct 2006 → Aug 2008 | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00395603 | Sep 2006 → Jun 2007 | cardiovascular disorder, diabetes mellitus | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00362206 | Sep 2006 → Sep 2008 | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00316095 | Apr 2006 → Aug 2007 | hyperlipidemia, hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00413972 | Apr → Nov 2006 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00289900 | Jan 2006 → Aug 2010 | hyperlipidemia, combined, 2 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00267267 | Jan 2006 → Jan 2007 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00947323 | Jan 2006 → Jul 2008 | erectile dysfunction, vascular disorder | Santa Casa de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT00267280 | Jan → Dec 2006 | hyperlipidemia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00267254 | Jan → Aug 2006 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00269217 | Jan 2006 → Jan 2007 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00651560 | Nov → Dec 2005 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00349375 | Nov 2005 → Sep 2008 | hyperlipidemia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00254475 | Nov 2005 → Sep 2006 | essential hypertension, hyperlipoproteinemia | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00242268 | Oct 2005 → ? | relapsing-remitting multiple sclerosis | Alabama Neurology Associates, PC | Unknown | No outcome recorded |
| Phase 3 | NCT00256178 | Oct 2005 → Mar 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00110435 | May → Dec 2005 | familial hypercholesterolemia, type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00541697 | Jan → Sep 2005 | type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00132717 | Jan 2005 → Jun 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00093899 | Nov 2004 → Sep 2005 | hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00171093 | Sep 2004 → Jan 2006 | essential hypertension, hyperlipidemia | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00650819 | Jun 2004 → Feb 2005 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00090298 | Apr → Dec 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00080275 | Mar 2004 → ? | hyperlipidemia | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00090168 | Jan → Oct 2004 | atherosclerosis, coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00652301 | Jul 2003 → Apr 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092690 | Jun 2003 → Mar 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092664 | Jan → Sep 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00157911 | Dec 2002 → Oct 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00053599 | Dec 2002 → Oct 2007 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 3 | NCT00092651 | Sep 2002 → Jun 2003 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092157 | May 2002 → Mar 2003 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00385931 | Jan 2002 → Apr 2003 | hyperlipidemia, hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00551447 | Jan 2002 → Mar 2003 | coronary artery disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00551876 | Dec 2001 → Jan 2003 | type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00389896 | Jul 2001 → Oct 2002 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092677 | Jan 2001 → Apr 2008 | aortic valve stenosis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03885921 | Oct 2000 → Jul 2003 | homozygous familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03884452 | May 2000 → May 2001 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00251576 | Nov 1999 → Mar 2004 | acute coronary syndrome | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00000553 | Sep 1994 → Feb 2001 | coronary artery disorder, myocardial ischemia | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00004266 | Aug 1993 → Jul 1999 | diabetic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00082251 | — | hyperlipidemia | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 471 trials | ||||||
| Phase 4 | NCT06856772 | Feb 2025 → Mar 2028 expected | atherosclerotic cardiovascular disease | Tor Biering-Sørensen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06785727 | Feb 2025 → Dec 2028 expected | transient ischemic attack | Prof. dr. Nathalie van der Velde | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06399783 | Oct 2024 → Oct 2027 expected | alopecia areata | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06523465 | Sep 2024 → Dec 2025 overdue | hypertensive disorder, primary aldosteronism | Third Military Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT07459972 | Mar 2024 → Mar 2025 | cirrhosis of liver, portal hypertension | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 4 | NCT05059626 | Dec 2023 → Dec 2025 overdue | endometriosis | Penn State University | Recruiting | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05613400 | Apr 2022 → Dec 2024 | type 2 diabetes mellitus | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT05133310 | Nov 2021 → Dec 2022 | acute lymphoblastic leukemia, infectious disease with sepsis | Hospital General de Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT05369091 | Dec 2020 → Oct 2021 | bone disorder | Postgraduate Medical Institute, Lahore | Completed | No outcome recorded |
| Phase 4 | NCT02533141 | Oct 2019 → Sep 2020 | — | Medical University of Vienna | Withdrawn | No outcome recorded |
| Phase 4 | NCT03452891 | Mar 2019 → Jul 2020 | periodontal disorder | University of Nebraska | Completed | No outcome recorded |
| Phase 4 | NCT03571802 | Jun 2018 → Jun 2025 | hyperlipidemia, obesity disorder | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 4 | NCT04177173 | Sep 2017 → Dec 2018 | rheumatoid arthritis | King Edward Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03419429 | Jan 2016 → Jun 2017 | chronic periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02378064 | May 2015 → Dec 2017 | atherosclerosis, coronary artery disorder | CHEOL WHAN LEE, M.D., Ph.D | Completed | No outcome recorded |
| Phase 4 | NCT02188121 | Feb 2015 → Oct 2020 | bipolar disorder, cardiovascular disorder, major depressive disorder, schizoaffective disorder +1 | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02015988 | Jan 2014 → Sep 2016 | acute coronary syndrome, hypertriglyceridemia, type 2 diabetes mellitus | Dnipropetrovsk State Medical Academy | Unknown | No outcome recorded |
| Phase 4 | NCT01952288 | Sep 2013 → Jun 2017 | traumatic brain injury | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT01563731 | Apr 2013 → Dec 2020 | hypertensive disorder, transient ischemic attack | Istituto Auxologico Italiano | Completed | No outcome recorded |
| Phase 4 | NCT05072405 | Jan → Dec 2013 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01282398 | Apr 2011 → Apr 2012 | cirrhosis of liver, portal hypertension | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01282385 | Apr 2011 → Apr 2014 | cirrhosis of liver, portal hypertension | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01564875 | Dec 2010 → May 2012 | chronic kidney disease, hyperlipidemia | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT01205347 | Oct 2010 → Sep 2013 | myocardial infarction | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT01185236 | Sep 2010 → Aug 2011 | type 2 diabetes mellitus | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01142336 | Jun 2010 → Oct 2015 | Alzheimer disease | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT01857843 | Nov 2009 → Nov 2013 | acute coronary syndrome | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01047423 | Aug 2009 → Aug 2011 | hypertensive disorder | Queen's University, Belfast | Withdrawn | No outcome recorded |
| Phase 4 | NCT00946166 | Jul 2009 → Aug 2011 | — | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded |
| Phase 4 | NCT00817843 | Apr 2009 → Sep 2010 | metabolic syndrome X | dr.Frank L.J. Visseren | Completed | No outcome recorded |
| Phase 4 | NCT01073007 | Apr 2009 → Jun 2014 | ischemic stroke | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00842920 | Dec 2008 → Aug 2020 | cognitive impairment with or without cerebellar ataxia | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 4 | NCT00906451 | Nov 2008 → May 2009 | myocardial infarction | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT00866229 | Apr 2008 → Mar 2010 | low density lipoprotein cholesterol, mild elevation of, systemic lupus erythematosus | Ramathibodi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00734123 | Apr 2008 → Apr 2009 | atherosclerosis | Hospital Arnau de Vilanova | Unknown | No outcome recorded |
| Phase 4 | NCT00672464 | Apr 2008 → Dec 2009 | schizoaffective disorder, schizophrenia | Duke University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00739050 | Sep 2007 → Feb 2008 | systemic lupus erythematosus | Organon and Co | Terminated | No outcome recorded |
| Phase 4 | NCT00654628 | Aug 2007 → Jul 2009 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00678743 | Aug 2007 → Aug 2009 | hyperlipidemia | Provident Clinical Research | Completed | No outcome recorded |
| Phase 4 | NCT00481351 | Jun 2007 → Jan 2010 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00404599 | Feb 2007 → Jul 2009 | hypertensive disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 4 | NCT01061450 | Nov 2006 → Jul 2009 | diastolic heart failure, hypertensive disorder | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT00442897 | Sep 2006 → Oct 2008 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00385658 | Aug 2006 → Mar 2007 | hyperlipidemia | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00423579 | Jul 2006 → Mar 2008 | coronary artery disorder, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00291863 | Feb 2006 | end stage renal failure | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00492765 | Feb 2006 → Apr 2010 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT01035320 | Jan 2006 → Jun 2012 | diabetes mellitus, impaired renal function disease | Karolinska Institutet | Completed | No outcome recorded |
| Phase 4 | NCT00652327 | Dec 2005 → Jul 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00157924 | Nov 2005 → Sep 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00166504 | Oct 2005 → Oct 2007 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00398294 | May 2005 → Apr 2006 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00259441 | Feb 2005 → Mar 2006 | kidney failure | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00397826 | Jan 2005 → Jan 2006 | hyperlipidemia | Cardinal Tien Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00189085 | Dec 2004 → Jul 2005 | metabolic syndrome X | UMC Utrecht | Completed | No outcome recorded |
| Phase 4 | NCT00146068 | Sep 2004 → Dec 2007 | multiple sclerosis | University of North Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00079638 | Apr 2004 → May 2005 | atherosclerosis, coronary artery disorder, diabetes mellitus, hyperlipidemia +1 | Kos Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00317993 | Apr → Jul 2004 | — | University of Cologne | Completed | No outcome recorded |
| Phase 4 | NCT00141141 | Jan 2004 → Apr 2007 | hyperlipoproteinemia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00650663 | Oct 2003 → Sep 2004 | atherosclerosis, hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00125593 | Jun 2003 → Aug 2010 | chronic kidney disease | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00451828 | Mar 2002 → Oct 2004 | coronary artery disorder, hyperlipidemia, hyperlipoproteinemia | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 4 | NCT00330980 | Apr 2000 → Mar 2004 | hyperlipidemia | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00307307 | Jan 2000 → Sep 2005 | atherosclerosis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT00159835 | Feb 1999 → Mar 2005 | cardiovascular disorder | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00471549 | Jun 1991 → Dec 1993 | type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00522158 | — | cardiovascular disorder, low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Baskent University | Completed | No outcome recorded |
| Phase 4 | NCT00306826 | ? → May 2009 | glucose metabolism disease | University of Leipzig | Withdrawn | No outcome recorded |
| Phase 4 | NCT00450840 | — | infectious disease with sepsis | Medical University of Vienna | Unknown | No outcome recorded |
| Phase not applicable45 trials | ||||||
| — | NCT07704918 | Dec 2026 → Dec 2027 expected | melanoma | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| — | NCT07102979 | Sep → Dec 2025 overdue | cirrhosis of liver | Chang Gung Memorial Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06431919 | Jun 2025 → Jan 2028 expected | acute kidney injury, cirrhosis of liver, cirrhotic cardiomyopathy, diastolic heart failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| — | NCT07692620 | Jun 2025 → May 2026 | tooth disorder | Maruwan Ali Alteer | Completed | No outcome recorded |
| — | NCT05677945 | Mar 2023 → Mar 2024 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT05525013 | Oct 2022 → Jun 2024 | periapical periodontitis | Cairo University | Completed | No outcome recorded |
| — | NCT05187715 | Feb 2022 → Oct 2023 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT04973800 | Jul 2021 → Feb 2023 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| — | NCT04575090 | Mar 2016 → Feb 2017 | statin toxicity | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT02465645 | Jun 2015 → Jan 2017 | esophageal varices | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01653223 | Jan 2013 → Dec 2024 overdue | congenital heart disease, heart valve disorder | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT01772719 | Aug 2012 → Nov 2016 | plasma cell myeloma | University of Louisville | Terminated | No outcome recorded |
| — | NCT01506505 | Jul 2012 → Jul 2013 | cerebrovascular disorder, peripheral arterial disease | UMC Utrecht | Completed | No outcome recorded |
| — | NCT01634906 | Jul 2012 → Mar 2013 | atherosclerosis, hyperlipidemia | Sint Franciscus Gasthuis | Completed | No outcome recorded |
| — | NCT01364675 | Jan 2012 → Jul 2016 | hypertensive disorder, prediabetes syndrome | Ramathibodi Hospital | Unknown | No outcome recorded |
| — | NCT00926055 | Sep 2011 → Sep 2012 | atherosclerosis | Korea University | Withdrawn | No outcome recorded |
| — | NCT01434745 | Sep 2011 → Oct 2014 | Smith-Lemli-Opitz syndrome | Oregon Health and Science University | Terminated | No outcome recorded |
| — | NCT01382511 | Jul 2011 → Dec 2014 | pachyonychia congenita | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT01259791 | Sep 2010 → Aug 2013 | statin toxicity | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT01178710 | Sep 2010 → Jun 2011 | congenital heart disease, heart valve disorder, rheumatic heart disease | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01179464 | Aug 2010 → May 2013 | metastatic carcinoma in the bone | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01085149 | May → Oct 2010 | hyperlipidemia | Hadassah Medical Organization | Unknown | No outcome recorded |
| — | NCT01106495 | May 2010 → Oct 2018 | atherosclerosis | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01241097 | Mar → Dec 2010 | — | Federal University of Bahia | Unknown | No outcome recorded |
| — | NCT00995670 | Mar 2010 → Sep 2013 | hyperglycemia | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT00990834 | Nov 2009 → Jun 2011 | myopathy | Scripps Health | Withdrawn | No outcome recorded |
| — | NCT02304926 | Jan 2009 → Dec 2011 | hyperlipidemia | FISABIO Foundation | Completed | No outcome recorded |
| — | NCT00879710 | Aug 2008 → Jul 2013 | hyperlipoproteinemia, type 1 diabetes mellitus, type 2 diabetes mellitus | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT00605995 | Feb 2008 → Aug 2011 | schizophrenia | New York State Psychiatric Institute | Terminated | No outcome recorded |
| — | NCT00746603 | Jan 2008 → Jul 2009 | carotid artery disorder | Columbia University | Terminated | No outcome recorded |
| — | NCT00531882 | Sep 2007 → Feb 2009 | cystic fibrosis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| — | NCT00487461 | May 2007 → Feb 2009 | acquired aneurysmal subarachnoid hemorrhage, intracranial vasospasm | University of Illinois at Chicago | Terminated | No outcome recorded |
| — | NCT01700530 | May 2007 → May 2011 | metabolic syndrome X, obesity disorder | University of Kansas Medical Center | Completed | No outcome recorded |
| — | NCT00475826 | Apr 2007 → ? | familial hypercholesterolemia | University of Sao Paulo | Unknown | No outcome recorded |
| — | NCT00365742 | Apr → Jun 2006 | hyperlipidemia | Chestnut Hill Health System | Completed | No outcome recorded |
| — | NCT00587678 | Jan 2006 → Oct 2009 | peripheral arterial disease | University of Virginia | Completed | No outcome recorded |
| — | NCT00285181 | Nov 2005 → Apr 2007 | — | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT00396513 | Sep 2005 → ? | polycystic ovary syndrome | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT00461968 | Feb 2005 → Apr 2007 | low density lipoprotein cholesterol, mild elevation of | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00114504 | Sep 2004 → Apr 2007 | atherosclerosis | Kurume University | Completed | No outcome recorded |
| — | NCT00365638 | Apr 2004 → Feb 2005 | polycystic ovary syndrome | Poznan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00309712 | Aug 2002 → Sep 2006 | hyperlipidemia, combined, 2, type 2 diabetes mellitus | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| — | NCT00125060 | Aug 2000 → Apr 2004 | heart disorder | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT00905541 | Nov 1998 → Mar 1999 | hyperlipidemia | University Hospital, Bonn | Completed | No outcome recorded |
| — | NCT02511418 | ? → Jan 2007 | chronic renal failure syndrome, hyperlipidemia, hypertensive disorder | Mayo Clinic | Completed | No outcome recorded |
Also used as a comparator or background therapy in 200 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05682911 Comparator | Jan → Jun 2018 | — | Jinnah Sindh Medical University | Completed | No outcome recorded |
| Phase 0 | NCT00720577 Comparator | Dec 2005 → Jul 2007 | peripheral arterial disease | Medtronic Endovascular | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT06379958 Comparator | Apr → Sep 2024 overdue | — | Modern Biosciences Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT04178980 Comparator | Jan 2020 → Jan 2022 | statin toxicity | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT02871687 Comparator | Apr 2016 → Mar 2021 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02714569 Background | Mar 2016 → Feb 2017 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02815722 Comparator | Jul 2013 → May 2014 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01859455 Background | Jul 2011 → Jul 2012 | hyperlipidemia, low density lipoprotein cholesterol, mild elevation of | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00929955 Comparator | Jun → Sep 2009 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 1 | NCT00839683 Comparator | Feb → Mar 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00655993 Comparator | Apr 2008 → Mar 2009 | chronic obstructive pulmonary disease | VA Loma Linda Health Care System | Completed | No outcome recorded |
| Phase 1 | NCT00208117 Comparator | Apr 2005 → Jan 2009 | acute coronary syndrome, coronary artery disorder, depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06016218 Comparator | Jan 2021 → Jan 2022 | dental caries | British University In Egypt | Completed | No outcome recorded |
| Phase 1/2 | NCT03247400 Comparator | Dec 2016 → Dec 2018 | vitiligo | Nicolaus Copernicus University | Completed | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT03896217 Comparator | May 2019 → Sep 2022 | secondary progressive multiple sclerosis | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT04406883 Comparator | Apr → Dec 2019 | — | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2 | NCT02787590 Comparator | Mar 2016 → Nov 2019 | Parkinson disease | University Hospital Plymouth NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT04803500 Comparator | Apr 2015 → Feb 2016 | bone resorption disease, disease of bone structure | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02256254 Comparator | Sep 2014 → Feb 2015 | disorder of defective peroxisome oxidative status | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT02072161 Background | Mar 2014 → Jan 2015 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01972178 Background | Nov 2013 → Jul 2014 | hyperlipidemia | Pronova BioPharma | Terminated | No outcome recorded |
| Phase 2 | NCT01890967 Background | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02120872 Comparator | Feb 2013 → Jan 2014 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2 | NCT02129231 Comparator | Feb 2012 → Jan 2014 | diabetic polyneuropathy, disorder of defective peroxisome oxidative status | University of Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT01342211 Background | Jul 2011 → Feb 2012 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01362218 Comparator | Oct 2010 → Apr 2012 | low density lipoprotein cholesterol, mild elevation of | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT01602029 Comparator | Aug 2010 → Jun 2013 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 2 | NCT01923077 Comparator | Apr 2010 → Sep 2013 | acute myocardial infarction | Svendborg Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01004705 Comparator | Sep 2009 → Mar 2011 | low density lipoprotein cholesterol, mild elevation of | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00804843 Comparator | Apr 2009 → Oct 2010 | atherosclerosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00647348 Comparator | Jan 2008 → Nov 2011 | secondary progressive multiple sclerosis | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT00477204 Comparator | May 2007 → Aug 2010 | hyperlipidemia, type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT00384865 Comparator | Sep 2006 → Oct 2009 | pulmonary arterial hypertension | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 2 | NCT00351286 Background | Mar 2006 → ? | intermittent vascular claudication, peripheral arterial disease | Angiogenix | Unknown | No outcome recorded |
| Phase 2 | NCT00157482 Background | Jan 2005 → Dec 2006 | type 2 diabetes mellitus | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT00688558 Background | Feb → Dec 2004 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00064792 Comparator | Jul 2003 → Dec 2010 | Smith-Lemli-Opitz syndrome | Forbes Porter, M.D. | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT03745300 Comparator | Mar → Dec 2017 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02372656 Comparator | Dec 2013 → Aug 2014 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02060032 Comparator | Feb → Nov 2013 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT01077206 Comparator | Sep 2010 → Jun 2013 | subarachnoid hemorrhage | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2/3 | NCT01160978 Comparator | Jun 2010 → Aug 2016 | disease related to transplantation, heart failure, kidney failure, liver failure +1 | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00831129 Comparator | Sep 2006 → Mar 2011 | prediabetes syndrome | University of Chicago | Completed | No outcome recorded |
| Phase 2/3 | NCT00566267 Background | Apr 2006 → Nov 2007 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 366 trials | ||||||
| Phase 3 | NCT03510715 Background | Aug 2018 → Feb 2020 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03510884 Background | May 2018 → Jan 2021 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03387670 Comparator | Mar 2018 → Jul 2024 | secondary progressive multiple sclerosis | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT02715726 Background | Jul 2016 → Aug 2018 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02476006 Background | Jun 2015 → Apr 2019 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02289963 Comparator | Jan 2015 → Apr 2016 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02107898 Background | Mar 2014 → Jan 2015 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02067949 Comparator | Feb 2014 → Feb 2015 | critical illness polyneuropathy | sara mostafa amin eladawy | Completed | No outcome recorded |
| Phase 3 | NCT01954394 Background | Dec 2013 → Jun 2017 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02030041 Background | Dec 2013 → Dec 2015 | hyperlipidemia | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT01926782 Background | Sep 2013 → Sep 2014 | hyperlipoproteinemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01420549 Comparator | Mar 2013 → Nov 2014 | hyperlipidemia | Ache Laboratorios Farmaceuticos S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01763866 Background | Jan → Nov 2013 | hyperlipidemia | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01709500 Background | Dec 2012 → May 2014 | familial hypercholesterolemia | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01678820 Comparator | Oct 2012 → Nov 2013 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT01644188 Background | Aug 2012 → May 2014 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01644175 Background | Jul 2012 → Apr 2014 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01623115 Background | Jul 2012 → Apr 2014 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01674712 Comparator | Jun 2012 → Oct 2013 | hyperlipidemia | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT01617655 Background | Jun 2012 → May 2014 | familial hypercholesterolemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01507831 Background | Jan 2012 → Nov 2014 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01061671 Comparator | Mar 2010 → Jan 2014 | chronic obstructive pulmonary disease | University of Minnesota | Terminated | No outcome recorded |
| Phase 3 | NCT01057758 Comparator | Sep 2009 → Jan 2013 | pneumonia | Assistance Publique Hopitaux De Marseille | Terminated | No outcome recorded |
| Phase 3 | NCT00862251 Comparator | Apr 2009 → Mar 2011 | cardiovascular disorder, diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00858637 Comparator | Mar 2009 → Mar 2010 | chronic kidney disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01099085 Comparator | Feb 2009 → Jun 2013 | gastric cancer | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00792337 Comparator | Dec 2008 → Aug 2009 | asthma | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00812955 Comparator | Nov 2008 → Jun 2009 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00854503 Comparator | Sep 2008 → Mar 2010 | hypertriglyceridemia 2, type 2 diabetes mellitus | University of Rome Tor Vergata | Completed | No outcome recorded |
| Phase 3 | NCT00984750 Background | Apr 2008 → May 2012 | hypertensive disorder, type 2 diabetes mellitus | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 3 | NCT00429442 Comparator | Mar 2008 → Mar 2011 | relapsing-remitting multiple sclerosis | Anna Tsakiri | Withdrawn | No outcome recorded |
| Phase 3 | NCT00664469 Comparator | Aug 2007 → Mar 2010 | hyperlipidemia | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| Phase 3 | NCT00575601 Comparator | Aug 2007 → Apr 2009 | polycystic ovary syndrome | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00532311 Comparator | Jul 2007 → Apr 2008 | hyperlipidemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00479388 Comparator | Jul 2007 → Jul 2008 | hyperlipidemia, combined, 2, hyperlipoproteinemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00731627 Comparator | Jan 2007 → Sep 2013 | subarachnoid hemorrhage | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 3 | NCT00461630 Background | Jan 2007 → Oct 2012 | coronary artery disorder, diabetes mellitus, peripheral arterial disease | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00261326 Comparator | Sep 2006 → Jan 2010 | multiple sclerosis, optic neuritis | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
| Phase 3 | NCT00300430 Comparator | Sep 2006 → Mar 2008 | coronary artery disorder, hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00344175 Comparator | Jun 2006 → Aug 2007 | coronary artery disorder, hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00286481 Comparator | Mar 2006 → May 2007 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00300456 Comparator | Mar 2006 → Mar 2007 | coronary artery disorder, hyperlipidemia, combined, 2 | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00352183 Comparator | Jan 2006 → Aug 2008 | cardiovascular disorder | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00271817 Comparator | Dec 2005 → Feb 2008 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00903409 Background | Nov 2005 → Jun 2008 | hypertriglyceridemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00246701 Comparator | Nov 2005 → Jun 2006 | hypertriglyceridemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00249899 Background | Nov 2005 → Mar 2007 | hyperlipoproteinemia | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00202878 Comparator | Oct 2005 → Sep 2014 | hyperlipidemia, myocardial infarction | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00251680 Comparator | Oct 2005 → May 2007 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00309777 Comparator | Sep 2005 → Oct 2006 | hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00120289 Background | Sep 2005 → Sep 2012 | atherosclerosis, coronary artery disorder, myocardial infarction, stroke disorder | Axio Research. LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00309738 Comparator | Sep 2005 → Oct 2006 | hyperlipidemia | Kowa Research Europe | Completed | No outcome recorded |
| Phase 3 | NCT00129402 Comparator | Aug 2005 → Jun 2007 | familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00423488 Comparator | Jul 2005 → Feb 2007 | coronary artery disorder, hyperlipidemia, type 2 diabetes mellitus | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00668343 Comparator | Apr 2005 → Mar 2008 | relapsing-remitting multiple sclerosis | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00651391 Comparator | Oct 2003 → Sep 2004 | atherosclerosis, hyperlipidemia | Organon and Co | Terminated | No outcome recorded |
| Phase 3 | NCT00542178 Background | Oct 2003 → Dec 2009 | diabetic retinopathy | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00127218 Background | Sep 2003 → Dec 2008 | atherosclerosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT00654446 Comparator | Sep 2002 → Apr 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00552097 Comparator | Jun 2002 → Apr 2006 | atherosclerosis, familial hypercholesterolemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00654173 Comparator | Jun 2002 → Sep 2004 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654407 Comparator | Nov 2001 → Sep 2004 | hyperlipoproteinemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00654537 Comparator | Apr 2001 → Oct 2004 | familial hypercholesterolemia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03882905 Background | Jan → Jul 2001 | hyperlipoproteinemia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00124072 Comparator | Jul 1998 → May 2008 | cardiovascular disorder | University of Oxford | Completed | No outcome recorded |
| Phase 459 trials | ||||||
| Phase 4 | NCT05657015 Comparator | Sep 2021 → May 2022 | periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05230472 Comparator | Jan → Dec 2021 | pneumonia caused by pseudomonas aeruginosa infection | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04140201 Comparator | Feb → Jun 2020 | diabetic retinopathy | Alaa Hassan ElBaz | Unknown | No outcome recorded |
| Phase 4 | NCT04049786 Comparator | Jun 2019 → Aug 2022 | obesity disorder | Natalia Valadares de Moraes | Unknown | No outcome recorded |
| Phase 4 | NCT04507373 Comparator | Aug 2018 → Dec 2021 | statin toxicity | University of Texas Southwestern Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03543774 Comparator | Jun 2018 → Mar 2020 | chronic kidney disease, hyperlipidemia | Hue University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 4 | NCT03653663 Comparator | Jan 2018 → Feb 2020 | myopathy, statin toxicity | Hartford Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04638400 Comparator | May 2017 → Aug 2021 | atherosclerosis, hyperlipidemia | paresh Dandona | Terminated | No outcome recorded |
| Phase 4 | NCT03084601 Comparator | Mar 2017 → Jan 2018 | dental pulp necrosis | Mahmoud M Saadoon | Completed | No outcome recorded |
| Phase 4 | NCT02994485 Comparator | Oct 2016 → Feb 2018 | portal hypertension | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT04044417 Comparator | Aug 2016 → May 2018 | periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02796378 Comparator | Jun 2016 → Jul 2021 | cardiovascular disorder, diabetes mellitus | University of Copenhagen | Unknown | No outcome recorded |
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02766803 Comparator | May 2016 → Jun 2017 | polycystic ovary syndrome | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT02428374 Comparator | May 2015 → Apr 2018 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02255682 Comparator | Jan 2015 → Dec 2016 | cardiovascular disorder, diabetes mellitus | University of Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT02001883 Comparator | Nov 2013 → Dec 2014 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02886299 Comparator | Oct 2013 → Jan 2016 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT01715714 Comparator | Nov 2012 → Apr 2019 | coronary artery disorder | University of Cologne | Completed | No outcome recorded |
| Phase 4 | NCT01686451 Comparator | Aug 2012 → Sep 2013 | hyperlipidemia | Wenzhou Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01666067 Comparator | Nov 2011 → Oct 2012 | hyperlipidemia | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01382472 Background | Sep 2011 → Dec 2016 | ST-elevation myocardial infarction | Helse Stavanger HF | Completed | No outcome recorded |
| Phase 4 | NCT01293097 Background | Jun 2010 → Oct 2011 | acute coronary syndrome, myocardial infarction | Peking University First Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01151306 Comparator | Jun 2010 → Apr 2013 | chronic obstructive pulmonary disease | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT01567826 Comparator | May 2010 → Feb 2012 | coronary artery disorder | Annapoorna Kini | Completed | No outcome recorded |
| Phase 4 | NCT00738985 Comparator | Nov 2009 → Sep 2010 | cardiovascular disorder, hyperlipidemia | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Withdrawn | No outcome recorded |
| Phase 4 | NCT00932620 Comparator | Jun 2009 → Apr 2010 | hyperlipidemia | University of Ioannina | Completed | No outcome recorded |
| Phase 4 | NCT00905905 Comparator | May → Dec 2009 | myocardial infarction | Brasilia Heart Study Group | Completed | No outcome recorded |
| Phase 4 | NCT02305355 Background | Feb 2009 → Feb 2011 | hypertriglyceridemia, type 2 diabetes mellitus | Kuhnil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00850460 Comparator | Feb 2009 → Feb 2013 | statin toxicity | Rockefeller University | Terminated | No outcome recorded |
| Phase 4 | NCT00819403 Comparator | Jan 2009 → Nov 2011 | metabolic syndrome X | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT00802100 Background | Dec 2008 → Sep 2009 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00861731 Comparator | Nov 2008 → Jul 2009 | chronic kidney disease, hyperlipidemia | Azienda Ospedaliero Universitaria di Sassari | Unknown | No outcome recorded |
| Phase 4 | NCT00712049 Comparator | Jun 2008 → ? | atherosclerosis, hyperlipidemia | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT00704548 Comparator | Jun 2008 → Sep 2009 | hypertensive disorder | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT00699023 Background | Jun 2008 → Oct 2009 | hyperlipidemia, type 2 diabetes mellitus | Federico II University | Completed | No outcome recorded |
| Phase 4 | NCT00656292 Comparator | Apr 2008 → Mar 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00669435 Comparator | Apr 2008 | hypertensive disorder | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT00680641 Comparator | Apr 2008 → Feb 2011 | pulmonary emphysema | University of East Anglia | Unknown | No outcome recorded |
| Phase 4 | NCT01021579 Comparator | Jan 2008 → Mar 2009 | polycystic ovary syndrome | Fasa University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01384058 Comparator | Nov 2007 → May 2010 | hyperlipidemia, type 2 diabetes mellitus | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 4 | NCT01011660 Comparator | Oct 2007 → Aug 2012 | essential hypertension | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00560170 Comparator | Sep 2007 → Jan 2008 | atherosclerosis | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00988364 Comparator | Mar 2007 → Feb 2008 | metabolic syndrome X | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00762164 Comparator | Mar 2007 → Apr 2009 | hyperlipidemia | Bronx VA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00753883 Comparator | Jul 2006 → May 2008 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00506961 Comparator | Jun 2006 → Jul 2007 | hyperlipidemia, type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00166530 Comparator | Nov 2005 → Feb 2007 | atherosclerosis | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00738296 Comparator | Apr → Dec 2005 | cardiovascular disorder | Hospital Universitario 12 de Octubre | Completed | No outcome recorded |
| Phase 4 | NCT00185107 Background | Mar → Oct 2005 | familial hypercholesterolemia | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00652717 Background | Feb 2005 | cardiovascular disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00466401 Background | Feb 2005 → Aug 2007 | hyperlipidemia | Ziv Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00736463 Comparator | Jan 2005 → Jan 2012 | — | Oregon Health and Science University | Unknown | No outcome recorded |
| Phase 4 | NCT00687076 Background | Apr 2004 → Dec 2010 | peripheral arterial disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00235950 Background | Jan 2004 → Mar 2006 | coronary artery disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00653835 Comparator | Sep 2003 → Aug 2004 | atherosclerosis, hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00652444 Background | Sep 2003 → Aug 2004 | hyperlipidemia | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00753779 Comparator | Nov 2002 → Jun 2003 | hyperlipoproteinemia | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00303277 Comparator | Aug 2002 → Apr 2005 | Alzheimer disease | Seattle Institute for Biomedical and Clinical Research | Completed | No outcome recorded |
| Phase not applicable31 trials | ||||||
| — | NCT07696585 Comparator | Jun → Sep 2026 expected | alopecia areata | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07194447 Comparator | Oct 2024 → Jul 2025 | — | University of Baghdad | Completed | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT05551871 Comparator | Oct 2022 → Dec 2023 | traumatic brain injury | Assiut University | Unknown | No outcome recorded |
| — | NCT05397405 Background | May 2022 → May 2026 overdue | cerebral artery stenosis | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05582317 Comparator | May 2021 → May 2022 | pulpitis | Suez Canal University | Completed | No outcome recorded |
| — | NCT03771053 Comparator | Jan 2018 → Mar 2019 | coronary artery disorder | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT03375580 Comparator | Dec 2017 → Aug 2019 | NAFLD1 | The First Affiliated Hospital of Guangdong Pharmaceutical University | Unknown | No outcome recorded |
| — | NCT03355027 Background | Nov 2017 → Sep 2019 | atherosclerosis | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT04885153 Background | Nov 2016 → Jul 2017 | diabetes mellitus, diabetic retinopathy, hyperlipidemia | Indonesia University | Completed | No outcome recorded |
| — | NCT03127631 Comparator | Oct 2015 → Dec 2026 expected | cardiovascular disorder, prostate cancer | McMaster University | Active not recruiting | No outcome recorded |
| — | NCT02490527 Background | Jun 2015 → Jul 2021 | statin toxicity | University of California, San Diego | Completed | No outcome recorded |
| — | NCT02269046 Comparator | Dec 2014 → Dec 2016 | hyperlipidemia | The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01702987 Comparator | Oct 2012 → Oct 2013 | hyperlipidemia, myopathy, statin toxicity | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT01101204 Comparator | Jul → Oct 2012 | hyperlipidemia, type 2 diabetes mellitus | Medical University of Silesia | Unknown | No outcome recorded |
| — | NCT01420328 Comparator | May 2011 → Jul 2015 | — | University at Buffalo | Completed | No outcome recorded |
| — | NCT01195428 Comparator | Oct 2010 → Oct 2011 | acute lung injury, adult acute respiratory distress syndrome | University of Oklahoma | Withdrawn | No outcome recorded |
| — | NCT01097785 Comparator | Mar 2009 → Jul 2014 | heart failure | University of Missouri-Columbia | Completed | No outcome recorded |
| — | NCT00691314 Comparator | Jun 2008 → Sep 2010 | atherosclerosis, transient ischemic attack | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00725829 Background | Jun 2008 → Jun 2009 | acute coronary syndrome | Jagiellonian University | Unknown | No outcome recorded |
| — | NCT00743197 Comparator | May 2008 → May 2010 | intermediate coronary syndrome | Northwestern University | Terminated | No outcome recorded |
| — | NCT00664846 Background | Apr 2008 → Dec 2010 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00572468 Comparator | Dec 2007 → Apr 2013 | prostate cancer | VA Office of Research and Development | Completed | No outcome recorded |
| — | NCT00443794 Comparator | Mar 2007 → Oct 2008 | cardiovascular disorder | St. John's Research Institute | Completed | No outcome recorded |
| — | NCT00716846 Comparator | Jun 2006 → Jul 2008 | — | Hamamatsu University | Completed | No outcome recorded |
| — | NCT00474123 Comparator | Jan 2006 → Jan 2009 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01103648 Comparator | Jun 2005 → May 2006 | hyperlipoproteinemia, prediabetes syndrome | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT01424891 Comparator | Apr 2004 → Jul 2006 | type 2 diabetes mellitus | Heidelberg University | Completed | No outcome recorded |
| — | NCT00588471 Comparator | Nov 2002 → Apr 2011 | coronary artery disorder | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT00704314 Comparator | Oct 2002 → Jul 2005 | cardiovascular disorder, diabetes mellitus, hyperlipidemia | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT00587717 Comparator | Sep 2002 → Mar 2006 | carotid artery disorder | Mayo Clinic | Completed | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-06 | Novartis Pharmaceuticals | New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting novartis.com ↗ |
| 2006-11-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Court of Appeals Affirms Teva's Generic Zocor® Exclusivity tevapharm.com ↗ |
| 2006-06-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives First U.S. Approval of Generic Zocor® Tablets; Product to be Shipped Immediately tevapharm.com ↗ |
| 2006-06-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Novartis' Sandoz Unit Seeks to Delay First FDA Approval of Generic Zocor® tevapharm.com ↗ |
| 2006-05-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Simvastatin Tablets; Provides Update on 180-Day Exclusivity tevapharm.com ↗ |
| 2006-01-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Simvastatin Tablets tevapharm.com ↗ |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 587 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | simvastatin | “The purpose of this study is to determine whether administration of lapaquistat acetate co-administered with atorvastatin, rosuvastatin or simvastatin (stable statin therapy)...” NCT00249899 ↗579“The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗ “Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and...” NCT01005290 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20...” NCT00850460 ↗ “Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin...” NCT02072161 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01057537 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01326676 ↗ “Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.” NCT06437574 ↗ “Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02107898 ↗ “Additionally, Cohorts 1 and 3 will include an assessment of potential drug-drug interaction with simvastatin to examine CYP3A4 inhibition by GSK2647544.” NCT01978327 ↗ “can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously” NCT01259791 ↗ “Treatment with ezetimibe/simvastatin versus rosuvastatin resulted in a similar improvement of carotid atherosclerotic plaque inflammation” PMID 31426749 ↗ Aug 2019 “The trial compared a Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide) to Standard Practice.” PMID 21205325 ↗ Jan 2011 “A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol.” NCT05963568 ↗ “polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily” PMID 33186492 ↗ Nov 2020 “the effects of simvastatin alone (S) or simvastatin + ezetimibe (S+E) were compared in a randomized, double-blind, cross-over study” PMID 24720535 ↗ Jan 2014 “Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.” NCT01342211 ↗ “A capsule of Polycap contained aspirin 100 mg, simvastatin 20 mg, hydrochlorothiazide 12.5 mg, ramipril 5 mg, and atenolol 50 mg.” PMID 39082406 ↗ Jul 2024 “the cardiovascular polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, and hydrochlorothiazide 12.5 mg) in the evening” PMID 23382539 ↗ Feb 2013 “Vytorin (simvastatin 20mg/ezetimibe 10mg), Atozet (atorvastatin 20mg/ezetimibe 10mg), Cretrol (rosuvastatin 10mg/ezetimibe 10mg)” NCT07307989 ↗ “To evaluate the efficacy of oral simvastatin + ezetimibe (Vytorin) in treating alopecia areata in subjects 18 years and older.” NCT01520077 ↗ “Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)” NCT00687076 ↗ “pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin” NCT06478940 ↗ “Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02289963 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01507831 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01954394 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01617655 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01644175 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01623115 ↗ “Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.” NCT06553157 ↗ “Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.” NCT04885153 ↗ “The material is a combination of 3Mix (cefixime, metronidazole, and ciprofloxacin) and a statin (Simvastatin).” NCT06925490 ↗ “Patients will be randomized to receive simvastatin 40 mg as monotherapy or in combination with ezetimibe 10 mg” NCT00475826 ↗ “The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.” NCT00389896 ↗ “Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days” NCT00652431 ↗ “Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy” NCT01926782 ↗ “conventional lipid management (atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg)” NCT05397405 ↗ “FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril” NCT01321255 ↗ “All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin” NCT01634906 ↗ “Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)” NCT01972178 ↗ “polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg” NCT01313702 ↗ “Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks” NCT01420328 ↗ “prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.” NCT03134157 ↗ “3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin” NCT03084601 ↗ “the median dosage of statin was equivalent to 20 mg/day of simvastatin” PMID 38018702 ↗ Nov 2023 “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.” NCT01644188 ↗ “10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin” NCT02001883 ↗ “statins(Atorvastatin 20mg/day or Simvastatin 20mg/day)” NCT00691314 ↗ “Simvastatin 20mg/d QN Po (half an hour before bedtime)” NCT03971019 ↗ “receive Simvastatin orally (20 mg to 40 mg ) per day” NCT04301336 ↗ “exercise in combination with simvastatin (40 mg/day)” PMID 23583255 ↗ Apr 2013 “Simvastatin: 80mg qd po for not more than 28days” NCT05658692 ↗ “Simvastatin (to 40mg without amlodipine)” NCT02850081 ↗ “EZE 10 mg/d plus simvastatin” PMID 15811480 ↗ Feb 2005 “simvastatin 20 mg daily” NCT00127218 ↗ “Simvastatin 80 mg” NCT01715714 ↗ “simvastatin” NCT03247400 ↗ “Simvastatin” NCT00249899 ↗ “Simvastatin” NCT04638400 ↗ “Simvastatin” NCT05550415 ↗ “Simvastatin” NCT01563731 ↗ “Simvastatin” NCT01702987 ↗ “simvastatin” NCT01890967 ↗ |
| Known as | Brand name: Simvastatin Normon, 40 mg | “Brand name: Simvastatin Normon, 40 mg” NCT04021498 ↗ |
| Known as | C10AA01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Flolipid | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Lacersa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | MK-733 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | MK0733 | “MK0733, simvastatin / Duration of Treatment: 27 Weeks” NCT00551447 ↗ |
| Known as | NSC-758706 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Ranzolont | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | SIM | “We recently showed capability of VPA/Simvastatin (SIM) combination to potentiate the antitumor activity of gemcitabine/nab-paclitaxel in vitro and in vivo PDAC preclinical models.” PMID 39300376 ↗ Sep 20242“The investigators hypothesize that simvastatin (SIM) may improve the efficacy of first- line Nivolumab and Oxaliplatin-based chemotherapy” NCT07213557 ↗ “Simvastatin (SIM)” NCT01335997 ↗ |
| Known as | SIMVA | “The purpose of this study was to examine the efficacy and safety of ezetimibe (EZE) coadministered with simvastatin (SIMVA) in a large cohort of African Americans with primary...” PMID 16749654 ↗ May 2006 |
| Known as | Simvador | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | simvastatin (Vytorin) | “simvastatin (Vytorin)” NCT00127218 ↗ |
| Known as | Simvastatin (ZOCOR) | “Simvastatin (ZOCOR)” NCT01332617 ↗1“Simvastatin (Zocor)” NCT00817843 ↗ |
| Known as | Simvastatin component of juvisync | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatin component of polycap | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatin component of simcor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatin component of vytorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Simvastatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00281476 ↗ |
| Known as | SMV | “Simvastatin (SMV) is one of the family members of statins, it has been showed in many previous studies that the simvastatin when dissolved with methylcellulose in situ gel with...” NCT04824898 ↗2“The purpose of the present study was to investigate the efficacy of autologous Platelet rich fibrin (PRF) or PRF and Simvastatin (SMV) with open flap debridement (OFD) in the...” NCT02120872 ↗ “Atorvastatin (ATV) and Simvastatin (SMV) are specific competitive inhibitors of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase.” NCT02060032 ↗ |
| Known as | statin therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658692 ↗ |
| Known as | Synvinolin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Known as | Zocor | “The purpose of this study is to determine the safety, tolerability and efficacy of a combination therapy interferon beta-1a(Avonex) plus simvastatin (Zocor) vs. interferon...” NCT00146068 ↗13“Both Niaspan (KOS Pharmaceuticals) and simvastatin (Zocor; Merck Pharmaceuticals) are commercially available drugs that are FDA approved for management of hyperlipidemia at the...” NCT00307307 ↗ “The purpose of this study is to see if a drug called simvastatin (brand name Zocor) beneficially affects the level of certain molecules (such as proteins) in the spinal fluid of people.” NCT01142336 ↗ “Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor® (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)” NCT00079638 ↗ “Simvastatin is a cholesterol-lowering drug approved by the FDA in 1991 and is now commercially available as Zocor (Merck) or as a generic agent.” NCT02534376 ↗ “The second group, run at the same time will take Zocor(simvastatin) 40 mg per day with standard counseling” NCT00365742 ↗ “The drug for treatment of elevated cholesterol is simvastatin (Zocor).” NCT00316095 ↗ “The Rho protein can be inhibited with a drug, simvastatin (Zocor®).” NCT00255242 ↗ “standard-care lipid-lowering therapy: Zocor or Lipitor” NCT01567826 ↗ “simvastatin [Zocor] 20, 40, or 80 mg” PMID 20136164 ↗ 2010 “Simvastatin (Zocor)” NCT00208117 ↗ “Zocor” NCT01293097 ↗ “Zocor” NCT00532311 ↗ |
| Known as | Zocor heart-pro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1064 ↗ |
| Action | Inhibit | “simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor)” NCT00004266 ↗ |
| Modality | Small molecule | “statin monotherapy (rosuvastatin [Crestor] 10, 20, or 40 mg; simvastatin [Zocor] 20, 40, or 80 mg;” PMID 20136164 ↗ 2010 |
| Route | Oral | “at tolerable oral doses” NCT00146068 ↗ |
| Target | HMGCR | “Statins, like simvastatin, inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase” NCT00399867 ↗ |